Today, WeightWatchers—now known as WW International—is undergoing a historic transformation, emerging from bankruptcy with a renewed strategy that positions it at the heart of women's health. On July 8, 2025, the company announced an ambitious undertaking: launching a specialized program to support women through perimenopause, menopause, and postmenopause. The purpose is clear: to go beyond weight loss and address overall well-being during this crucial stage of life.

What does this new program include?

• Hormone replacement therapy (HRT) and access to clinical treatments through its platform —including GLP-1 as Wegovy— integrated with nutritional counseling and behavioral coaching.
• Personalized notes based on age, hormonal health history, and specific metabolic challenges of menopause (such as insulin and body weight gain).
• Community support : frequent online workshops, Facebook groups with over 27,000 members, a dedicated "Menopause Hub," and updates on their app industryintel.com .

The science behind the change

Internal studies and user testimonials show that menopausal women using this integrated approach lose 3.8 times more weight than those following traditional methods. These figures reflect not only weight loss but also a positive impact on quality of life, nutritional status, and emotional well-being.

The financial and corporate strategy

• Financial restructuring : WW eliminated US$1.15 billion of debt and relisted on Nasdaq, reducing leverage and improving its position to invest in clinical services.
• High-caliber team : appointment of Dr. Kim Boyd, an expert in metabolic and women's health, as CMO, and the addition of executives from Eli Lilly (Mike Mason), One Medical and Calibrate.
• Clinical alliances : direct collaboration with Novo Nordisk to distribute Wegovy via telemedicine, offering medicines without compounded formulations or legal risks.

Ecosystem for women aged 40 to 60

• Market data : The menopause health sector could reach US$18.85 billion this year, and WW expects to capture a solid share thanks to its reputation and community.
• GLP-1 + lifestyle synergy : Patients who combine branded GLP-1 injectables with clinical coaching lose up to 30% more than those who only take medication.
• Specialized workshops : Since 2024, WW has offered three weekly Zoom sessions focused exclusively on menopause, addressing topics such as hot flashes, emotional changes, and nutrition.

Why does this matter?

1. Break the stigma : talking openly about symptoms like insomnia or mood swings establishes a safe space, backed by data and community.
2. Health with a female focus : instead of deriving male protocols, methods are designed based on biomarkers and female hormonal needs.
3. Beyond weight : the program promotes holistic well-being — bone health, cholesterol management, sleep, mental health — not just a scale.
4. Sustainable and scalable model : employees and insurers value this hybrid approach (pharmaceuticals + lifestyle), creating a potential for recurring revenue in the medium to long term.

Real testimonials

On Reddit, several women in perimenopause describe how WW allows them to lose weight continuously even after 40-50 years of age, exemplifying that the program works without medication.

“I’ve lost 37 lbs in 5 months at 58 years old… and only with my daily points, without a gym or medication.”

And others agree:

“WW works at all ages… if you want to speed things up you can add HRT or GLP-1.”

What's next?

• Formal launch of the program in the second half of 2025.
• Pilots with insurance companies and businesses to offer corporate group plans.
• Exploration of clinical metrics: blood pressure, bone density, mental well-being, and long-term cardiovascular mortality.

WW International has executed a smart strategic maneuver: capitalizing on the demand for women's health during menopause by integrating clinically supported GLP-1 therapies, an active community, and the weight of its historical experience. This hybrid model could mark a turning point in women's public health.